
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **November 2021**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

On November 3, 2021, Evogene Ltd., or Evogene, announced the commercial launch of *resuli*[™], the first microbiome-based product for yield improvement of its subsidiary Lavie Bio Ltd., or Lavie Bio. A copy of the press release is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K, or this Form 6-K, and is incorporated herein by reference.

The contents of Exhibit 99.1 to this Form 6-K, excluding the statements of Lavie Bio's CEO and of an early adopter farmer, are incorporated by reference into the registration statements on Form F-3 (File No. 333-253300) and on Form S-8 (File Nos. 333-193788, 333-201443, 333-203856 and 333-259215) of Evogene, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

Date: November 3, 2021

By: /s/ Dorit Kreiner

Dorit Kreiner
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.

99.1

DESCRIPTION

[Press Release: Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement - *result*TM](#)



**Lavie Bio Announces Commercial Launch of its First
Microbiome-Based Product for Yield Improvement - *result*TM**

***result*TM inoculant initially introduced for spring wheat in North
Dakota, following positive four-year field trials**

Rehovot, Israel – November 3, 2021 — Lavie Bio Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality and agricultural productivity and sustainability through the introduction of microbiome-based products, announced today the commercial launch of its first product, LAV.211, an inoculant for yield improvement, under the brand name *result*TM.



Logo of *result*TM inoculant

The first phase of marketing and initial market penetration for the upcoming 2022 spring wheat season will be limited to target regions in North Dakota, and will be accomplished under a distribution agreement with United Agronomy, as recently announced¹. These initial sales are expected to be recognized in 2022. The development of *result*TM included positive four-year field trials in multiple locations and commercial validation through broad-acre fields under standard farmer practices in target locations ('early adopter network').

The results achieved in the field trials have demonstrated that *result*TM has the potential to contribute an additional 3–4 bushels per acre and showed increased yield improvement compared with industry benchmarks. According to Lavie Bio's estimates and assuming average commodity prices, this could provide spring wheat farmers an average of \$20 of additional revenue per farmed acre, which may translate to a 50% increase or more in profit². There are an estimated 25 million acres of spring wheat in North America³, with about 6 million in North Dakota⁴.

¹ https://www.evogene.com/press_release/lavie-bio-and-united-agronomy-announce-signing-of-distribution-agreement-for-lavie-bios-inoculant-product/

² <https://www.ndsu.edu/agriculture/ag-hub/ag-topics/farm-management/crop-economics/projected-crop-budgets>

³ <https://www.ers.usda.gov/webdocs/publications/86210/whs-171.pdf?v=43083>, pg. 18; Phillips McDougall, 2017, <https://www150.statcan.gc.ca/t1/tb11/en/tv.action?pid=3210035901>

⁴ <https://ndwheat.com/buyers/NorthDakotaWheatClasses/HardRedSpringWheat/>

Following this initial commercial introduction, Lavie Bio intends to expand through additional distribution channels and to evaluate the opportunities for *result*TM in additional territories for spring wheat, and for application to additional cereals. In parallel, the company expects to increase its production capabilities to support such expansion.

Kyle Nichols, a farmer from Palermo, North Dakota, and part of the 'early adopter network' of *result*TM stated: “As a farmer, I want the most profitability out of my acres. Maximizing production and raising a healthy crop is very important to me, and with *result*TM from Lavie Bio it's very clear to see the benefit it brings to my farm operation. Wheat treated with *result*TM produces a better stand, healthier grain, and higher yields. Sitting in the combine and watching the combine monitor you can clearly see the benefit from *result*TM compared to my untreated acres - the bushels are better quality and there are more of them.”

Mr. Ido Dor, Chief Executive Officer, Lavie Bio, stated: “I am very proud that Lavie Bio has reached this milestone and is launching its first product. Our extended trials have indicated that *result*TM is an excellent product providing strong value to farmers by significantly improving yield and productivity. Furthermore, *result*TM's rapid development process - six years from concept to initial marketing - and the progress being achieved by other microbiome products in our pipeline, is possible only through the use of Lavie Bio's *BDD platform*, powered by Evogene's 'MicroBoost AI' engine, a very important competitive advantage for our Company.”

About LAV.211/*result*[™]:

LAV.211/*result*[™] is a microbial based inoculant that has been designed to empower plant performance based on its ability to improve the uptake and assimilation of nutrients, thereby increasing yield, and improving growers' profitability, while contributing to environmental sustainability and soil health. LAV.211/*result*[™] is intended to be applied as a seed treatment and is formulated as a water dispersible granule (WDG).

About Lavie Bio Ltd.:

Lavie Bio, a subsidiary of Evogene Ltd., aims to improve food quality, sustainability and agriculture productivity through the introduction of microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, harnessing the power of big data and advanced informatics, for the discovery, optimization and development of bio-stimulant and bio-pesticide products. Corteva, Inc. holds approximately 28% in Lavie Bio. For more information, please visit www.lavie-bio.com.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN, TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ag Ltd. **For more information, please visit:** www.evogene.com.

Forward Looking Statements:

This press release contains “forward-looking statements” relating to future events. These statements may be identified by words such as “may”, “could”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates”, or words of similar meaning. For example, Evogene and Lavie Bio are using forward-looking statements in this press release when they discuss Lavie Bio’s pipeline and commercialization plans, including future opportunities and territories, and the potential benefits of LAV.211/result™. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, those risk factors contained in Evogene’s reports filed with the applicable securities authorities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Evogene Investor Contact:

Rivka Neufeld
Investor Relations
E: IR@evogene.com
T: +972-8-931-1900

US Investor Relations:

Joseph Green
Edison Group
E: jgreen@edisongroup.com
T: +1 646-653-7030

Laine Yonker
Edison Group
E: lyonker@edisongroup.com
T: +1 646-653-7035
